Thermo Fisher Scientific Inc. will buy Affymetrix Inc. in a roughly $1.3 billion cash deal that would boost its biogenetic analysis portfolio, the company said Friday.

Under the terms of the deal, which requires approval by Affymetrix shareholders, Thermo Fisher is to pay $14 a share in cash. Affymetrix’s shares closed Friday at $9.21.

Thermo...